| 2026-10-26 16:53 |
8-K |
["8.01"] |
merger agreement |
0.98
|
Rallybio acquiring Avenzo via definitive merger agreement signed May 31, 2026; closing expected November 6, 2026. |
SEC · detail |
| 2026-09-09 16:30 |
8-K |
["5.02", "9.01"] |
merger agreement |
0.92
|
CFO transition tied to pending merger with Avenzo; employment terminates at merger closing. |
SEC · detail |
| 2026-06-01 08:07 |
8-K |
["1.01"] |
merger agreement |
0.98
|
Rallybio entered definitive merger agreement to acquire Avenzo Therapeutics on May 31, 2026. |
SEC · detail |
| 2026-05-04 07:54 |
8-K |
["1.01", "1.02", "9.01"] |
other |
0.15
|
Rallybio's merger with Candid terminated; Candid pursuing alternative deal with UCB. Rallybio receives $50M termination fee. |
SEC · detail |